The two GLP-1 treatments available are sold under the brand names Byetta and Victoza. The drugs, however, are not very popular with consumers, and are not nearly as popular as they deserve to be, according to Edelman. “It’s a case of clinical inertia on behalf of doctors,” Edelman says regarding one reason why more GLP-1 prescriptions aren’t being written.
Tag: Victoza
IDegLira is a combination of Tresiba (insulin degludec), a once-daily basal insulin analogue with an ultra-long duration of action, and Victoza (liraglutide), the once-daily human GLP-1 analogue for the treatment of type 2 diabetes.
The FDA is evaluating unpublished new findings by a group of academic researchers that suggest an increased risk of pancreatitis, or inflammation of the pancreas, and pre-cancerous cellular changes called pancreatic duct metaplasia in patients with type 2 diabetes treated with a class of drugs called incretin mimetics.
New data from observational studies in the UK shows that patients with type 2 diabetes experience greater reduction of HbA1c levels when using Victoza compared to Byetta (exenatide) and DPP-4 inhibitors. Victoza...
Novo Nordisk’s widely popular GLP-1 analog Victoza made headlines at the beginning of the year when celebrity chef Paula Deen became a spokesperson…
"Paula Deen is not the diabetes poster child," said Ambre Morely, associate director of product communications at Novo Nordisk. "She's an everyday person with type 2 diabetes...
Paula Deen has been privately suffering from type 2 diabetes for three years. Now she’s gone public with both her diabetes and her treatment with Victoza...
After days of rumors regarding Paula Deen's diabetes diagnosis, the woman dubbed the Queen of Southern Cuisine has announced that she and her sons have partnered up with Novo Nordisk to launch Diabetes in a New Light™, a national initiative to help adults find simple ways...
Victoza, Novo Nordisks best selling type 2 diabetes drug is now commercially available in China. Victoza, (liraglutide injection), the first once-daily human Glucagon-Like Peptide-1 (GLP-1) analog, was approved for type 2 diabetes by the Chinese State Food and Drug Administration in March 2011...
Following a review of new data from a 52-week clinical trial, the European Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion on the usage of Novo Nordisk’s basal insulin analogue, Levemir, as add-on therapy to Novo Nordisk’s GLP-1 analogue, Victoza, in combination with metformin in patients with type 2 diabetes...